Connect with us

Business

Is It The Time To Invest In GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)?

Published

on

In last trading session, the shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) declined more than 1% to close the day at $84.75. The decline came at a share volume of 339,087 compared to average share volume of 1.08 million.

The buzz

Lately, the sentiment towards marijuana stocks have witnessed a radical change. Most of the market experts are of view that marijuana firms should be avoided. However, the one exception to this group is GW Pharmaceuticals. The company recently announced positive late-stage data for its marijuana-derived medication ‘Epidiolex’ in a rare and severe form of epilepsy named Dravet syndrome, leading its shares to gain.

Specifically, GW announced that Epidiolex resulted in a statistically significant decline in the monthly seizures required in people suffering with Dravet syndrome against those getting a placebo in the trial. This trial offers some of the first convincing data that marijuana-based drugs can indeed work as effective treatments for severe, life-threatening conditions.

The plans

Going ahead, GW Pharmaceuticals is currently evaluating Epidiolex in a second Dravet syndrome trial, along with 2 other late-stage studies for another form of epilepsy named Lennox-Gastaut syndrome. These pivotal-stage trials have the potential to offer a solid empirical platform that marijuana-derived medications can be effective and safe treatments for severe diseases with limited treatment options.

It is vital to note that GW Pharmaceutical still faces a major regulatory obstacle before the U.S. FDA approves the medication for its childhood epilepsy problems. And this problem may be much difficult to overcome than it seem.

The expectations

The FDA presently has not much experience with such form of drugs, and its website seems vague when it comes to actual perspective on marijuana-based drugs. As such, the U.S. FDA could set an extremely high bar in respect of efficacy and safety for Epidiolex. However, the agency has been prepared to approve expanded access to this drug for some patients during Epidiolex’s ongoing clinical trials. GW’s upcoming data for Epidiolex could validate marijuana-based medications as a whole.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement